Mcp

Metoclopramide, the active ingredient in Mcp, is a dopamine D2 receptor antagonist presented as an oral dosage form for oral use. It is used to treat nausea, vomiting, gastroparesis and gastro‑oesophageal reflux disease in adults.

GNH USA supplies Mcp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on dopaminergic pathways that regulate nausea and gastric motility.

- Nausea and vomiting: reduces episodes by blocking dopamine receptors in the chemoreceptor trigger zone. - Gastroparesis: enhances gastric emptying and improves symptoms of delayed stomach emptying. - Gastro‑oesophageal reflux disease (GERD): decreases reflux episodes by increasing lower oesophageal sphincter tone.

Metoclopramide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or akathisia - Headache - Dizziness - Gastrointestinal upset (nausea, abdominal cramps)

Serious or Rare Side Effects: - Extrapyramidal reactions (e.g., dystonia, parkinsonism) - Tardive dyskinesia with long‑term use - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Seizures - Anaphylactic or severe allergic reactions

Before prescribing Metoclopramide, clinicians should consider several safety aspects.

- Assess renal function: adjust use in severe renal impairment. - Monitor for extrapyramidal symptoms: observe for involuntary movements, especially in the first days of therapy. - Avoid in patients with known hypersensitivity: discontinue if rash or angioedema develops. - Use caution in pregnancy: limited data, weigh benefits against potential risks. - Store at below 25°C: keep in the original pack, protect from moisture.

Metoclopramide can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive dopamine blockade may increase extrapyramidal risk. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise metoclopramide plasma concentrations. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Anticholinergics: may blunt the pro‑kinetic effect of metoclopramide. - Diabetic agents: metoclopramide can affect glucose control; monitor blood sugar levels.